EGFR and adenocarcinoma: In conclusion, for the relatively large sample capacity, more effective tumor samples and the use of a more sensitive method in our study, our data should better represent the current situation of TKIs sensitive EGFR mutations in Chinese patients with NSCLS, especially the mutation status of squamous-cell carcinoma, adenocarcinoma and adenosquamous carcinoma.